1577 related articles for article (PubMed ID: 26376137)
1. Acute Myeloid Leukemia.
Döhner H; Weisdorf DJ; Bloomfield CD
N Engl J Med; 2015 Sep; 373(12):1136-52. PubMed ID: 26376137
[No Abstract] [Full Text] [Related]
2. The combination of fludarabine, cytarabine and etoposide is an active and well-tolerated regimen in relapsed/refractory acute myeloid leukemia.
Aldoss I; Ji L; Haider M; Pullarkat V
Acta Haematol; 2014; 131(4):202-7. PubMed ID: 24296475
[TBL] [Abstract][Full Text] [Related]
3. Remission induction, consolidation and novel agents in development for adults with acute myeloid leukaemia.
Hamadani M; Awan FT
Hematol Oncol; 2010 Mar; 28(1):3-12. PubMed ID: 19645073
[TBL] [Abstract][Full Text] [Related]
4. Novel therapeutic strategies for AML in 2012.
Tallman MS
Hematology; 2012 Apr; 17 Suppl 1():S43-6. PubMed ID: 22507777
[TBL] [Abstract][Full Text] [Related]
5. High dose ara-C combined with autologous peripheral blood stem cell transplantation in the treatment of acute myelogenous leukemia: the question is still not answered.
Bruserud O; Ernst P
Stem Cells; 2000; 18(6):459-60. PubMed ID: 11072036
[No Abstract] [Full Text] [Related]
6. Re-analysis of the outcomes of post-remission therapy for acute myeloid leukemia with core binding factor according to years of patient enrollment.
Shin HJ; Kim HJ; Sohn SK; Min YH; Won JH; Kim I; Yoon HJ; Lee JH; Jo DY; Joo YD; Jung CW; Lee KH; ; Chung JS; Ahn JS; Kim SJ; Lee JH; Choi SJ; Lee JH; Bae SH; Hong DS; Zang DY; Kim SH; Lee JL; Bang SM
Jpn J Clin Oncol; 2010 Jun; 40(6):556-66. PubMed ID: 20185460
[TBL] [Abstract][Full Text] [Related]
7. Prognosis of secondary acute myeloid leukemia is affected by the type of the preceding hematologic disorders and the presence of trisomy 8.
Koh Y; Kim I; Bae JY; Song EY; Kim HK; Yoon SS; Lee DS; Park SS; Park MH; Park S; Kim BK
Jpn J Clin Oncol; 2010 Nov; 40(11):1037-45. PubMed ID: 20587614
[TBL] [Abstract][Full Text] [Related]
8. [Current treatment of acute myeloid leukemia].
Ohtake S
Rinsho Ketsueki; 2012 Oct; 53(10):1560-70. PubMed ID: 23037728
[No Abstract] [Full Text] [Related]
9. Treatment for relapsed acute myeloid leukemia: what is new?
Ofran Y; Rowe JM
Curr Opin Hematol; 2012 Mar; 19(2):89-94. PubMed ID: 22227525
[TBL] [Abstract][Full Text] [Related]
10. The role of peripheral blood stem cells as rescue after myeloablative therapy.
Reiffers J; Marit G; Boiron JM; Rice A; Bernard P; Vezon G
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():212-4. PubMed ID: 2565746
[No Abstract] [Full Text] [Related]
11. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M
Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345
[TBL] [Abstract][Full Text] [Related]
12. Strategies for acute myelogenous leukemia.
Gale RP; Butturini A
Bone Marrow Transplant; 1991; 7 Suppl 2():58. PubMed ID: 1878721
[No Abstract] [Full Text] [Related]
13. [Treatment of adult patients with acute myeloid leukemia (excluding acute promyelocytic leukemia)].
Usui N
Rinsho Ketsueki; 2014 Oct; 55(10):1808-16. PubMed ID: 25297744
[No Abstract] [Full Text] [Related]
14. Cytarabine dose for acute myeloid leukemia.
Löwenberg B; Pabst T; Vellenga E; van Putten W; Schouten HC; Graux C; Ferrant A; Sonneveld P; Biemond BJ; Gratwohl A; de Greef GE; Verdonck LF; Schaafsma MR; Gregor M; Theobald M; Schanz U; Maertens J; Ossenkoppele GJ;
N Engl J Med; 2011 Mar; 364(11):1027-36. PubMed ID: 21410371
[TBL] [Abstract][Full Text] [Related]
15. Successful second autologous blood stem cell transplantation after G-CSF-combined conditioning for the treatment of high-risk acute myelogenous leukemia.
Takamatsu Y; Teshima T; Akashi K; Inaba S; Harada M; Niho Y
Bone Marrow Transplant; 1994 Mar; 13(3):325-7. PubMed ID: 7515302
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of FLAG as initial induction chemotherapy followed by autologous hematopoietic stem cell transplantation after IBu conditioning regimen in acute myeloid leukemia with FLT3 mutations].
Wang B; Yang B; Dong W; Liu D; Ling Y; Cao X
Zhonghua Xue Ye Xue Za Zhi; 2014 Jul; 35(7):653-5. PubMed ID: 25052613
[No Abstract] [Full Text] [Related]
17. Effect of allogeneic hematopoietic stem cell transplantation from matched siblings or unrelated donors during the first complete remission in patients with cytogenetically normal acute myeloid leukemia.
Hsieh YY; Hong YC; Hsiao LT; Yu YB; Liu JH; Gau JP; Lin HN; Hsu YN; Chiou TJ; Chen PM; Tzeng CH; Liu CY
Eur J Haematol; 2011 Mar; 86(3):237-45. PubMed ID: 21155895
[TBL] [Abstract][Full Text] [Related]
18. [Current therapy for acute myeloid leukemia and acute promyelocytic leukemia].
Miyawaki S
Rinsho Ketsueki; 2014 Jan; 55(1):31-41. PubMed ID: 24492035
[No Abstract] [Full Text] [Related]
19. Outcome of patients with acute myelogenous leukemia after second salvage therapy.
Giles F; O'Brien S; Cortes J; Verstovsek S; Bueso-Ramos C; Shan J; Pierce S; Garcia-Manero G; Keating M; Kantarjian H
Cancer; 2005 Aug; 104(3):547-54. PubMed ID: 15973664
[TBL] [Abstract][Full Text] [Related]
20. Complete remission following donor PBSC after low-dose cytarabine chemotherapy for early relapse of acute myelogenous leukemia after allogeneic stem cell transplantation.
Trenschel R; Bernier M; Stryckmans P; Verhest A; Badjou R; Crombez P; Bron D
Bone Marrow Transplant; 1997 Feb; 19(4):381-3. PubMed ID: 9051249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
